Effectiveness of Major Ozone Autohemotherapy in the Treatment of Fibromyalgia Syndrome

NCT ID: NCT05034770

Last Updated: 2022-08-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 45 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-01-01
• Study Completion Date: 2022-01-11

Brief Summary

Patients who were admitted to the Physical Medicine and Rehabilitation (PMR) outpatient clinic of our hospital between January 2017 and December 2020 and were treated with Major ozone autohemotherapy with a diagnosis of Fibromyalgia syndrome will include to the study. Visual anolog scale (VAS), Fibromyalgia Impact Questionnare (FIQ) and Short Form Health Survey-36 (SF-36) scores of the patients before and after treatment were recorded. Statistical analysis of these outcome scores will be made.

Conditions

Fibromyalgia Syndrome

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Interventions

major ozone autohemotherapy

This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.

Intervention Type: OTHER

Eligibility Criteria

Exclusion Criteria

• has pregnancy,
• has primary romatological disease,
• has primary psychiatric disease
• <18, >60 years old patients

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Emine Dundar Ahi, MD

OTHER

Sponsor Role: lead

Responsible Party

Emine Dundar Ahi, MD

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Private Medar Hospital

Kocaeli, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

2020-161

Identifier Type: -

Identifier Source: org_study_id